H.C. Wainwright Downgrades ChemoCentryx (CCXI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel rattle AI trade
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil prices set for fourth straight monthly gains as tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts CCXI Hot Sheet
Price: $8.36 -15.9%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 48 | New: 9
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 48 | New: 9
Join SI Premium – FREE
H.C. Wainwright analyst Edward White downgraded ChemoCentryx (NASDAQ: CCXI) from Buy to Neutral with a price target of $52.00 (from $101.00).
For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.
Shares of ChemoCentryx closed at $50.43 yesterday.
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $875 at Baird
- Citi cuts Acumen Pharmaceuticals to neutral after trial failure
- Boot Barn (BOOT) PT Lowered to $175 at Jefferies, 'We recommend buying BOOT'
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
